Cargando…
Integrin αvβ6-specific therapy for pancreatic cancer developed from foot-and-mouth-disease virus
Goals of investigation: The 5-year survival rate for pancreatic ductal adenocarcinoma (PDAC) has remained at <5% for decades because no effective therapies have been identified. Integrin αvβ6 is overexpressed in most PDAC and represents a promising therapeutic target. Thus, we attempted to develo...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053198/ https://www.ncbi.nlm.nih.gov/pubmed/32194845 http://dx.doi.org/10.7150/thno.38702 |
_version_ | 1783502994817417216 |
---|---|
author | Moore, Kate M. Desai, Ami Delgado, Bea de Luxán Trabulo, Sara Maria David Reader, Claire Brown, Nicholas F. Murray, Elizabeth R. Brentnall, Adam Howard, Philip Masterson, Luke Zammarchi, Francesca Hartley, John A. van Berkel, Patrick H. Marshall, John F. |
author_facet | Moore, Kate M. Desai, Ami Delgado, Bea de Luxán Trabulo, Sara Maria David Reader, Claire Brown, Nicholas F. Murray, Elizabeth R. Brentnall, Adam Howard, Philip Masterson, Luke Zammarchi, Francesca Hartley, John A. van Berkel, Patrick H. Marshall, John F. |
author_sort | Moore, Kate M. |
collection | PubMed |
description | Goals of investigation: The 5-year survival rate for pancreatic ductal adenocarcinoma (PDAC) has remained at <5% for decades because no effective therapies have been identified. Integrin αvβ6 is overexpressed in most PDAC and represents a promising therapeutic target. Thus, we attempted to develop an αvβ6-specific peptide-drug conjugate (PDC) for therapy of PDAC. Methodology: We conjugated the DNA-binding pyrrolobenzodiazepine (PBD)-based payload SG3249 (tesirine) to an αvβ6-specific 20mer peptide from the VP1 coat protein of foot-and-mouth-disease virus (FMDV) (forming conjugate SG3299) or to a non-targeting peptide (forming conjugate SG3511). PDCs were tested for specificity and toxicity on αvβ6-negative versus-positive PDAC cells, patient-derived cell lines from tumor xenografts, and on two different in vivo models of PDAC. Immunohistochemical analyses were performed to establish therapeutic mechanism. Results: The αvβ6-targeted PDC SG3299 was significantly more toxic (up to 78-fold) for αvβ6-expressing versus αvβ6-negative PDAC cell lines in vitro, and achieved significantly higher toxicity at equal dose than the non-targeted PDC SG3511 (up to 15-fold better). Moreover, SG3299 eliminated established (100mm(3)) Capan-1 PDAC human xenografts, extending the lifespan of mice significantly (P=0.005). Immunohistochemistry revealed SG3299 induced DNA damage and apoptosis (increased γH2AX and cleaved caspase 3, respectively) associated with significant reductions in proliferation (Ki67), β6 expression and PDAC tumour growth. Conclusions: The FMDV-peptide drug conjugate SG3299 showed αvβ6-selectivity in vitro and in vivo and can specifically eliminate αvβ6-positive cancers, providing a promising new molecular- specific therapy for pancreatic cancer. |
format | Online Article Text |
id | pubmed-7053198 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-70531982020-03-19 Integrin αvβ6-specific therapy for pancreatic cancer developed from foot-and-mouth-disease virus Moore, Kate M. Desai, Ami Delgado, Bea de Luxán Trabulo, Sara Maria David Reader, Claire Brown, Nicholas F. Murray, Elizabeth R. Brentnall, Adam Howard, Philip Masterson, Luke Zammarchi, Francesca Hartley, John A. van Berkel, Patrick H. Marshall, John F. Theranostics Research Paper Goals of investigation: The 5-year survival rate for pancreatic ductal adenocarcinoma (PDAC) has remained at <5% for decades because no effective therapies have been identified. Integrin αvβ6 is overexpressed in most PDAC and represents a promising therapeutic target. Thus, we attempted to develop an αvβ6-specific peptide-drug conjugate (PDC) for therapy of PDAC. Methodology: We conjugated the DNA-binding pyrrolobenzodiazepine (PBD)-based payload SG3249 (tesirine) to an αvβ6-specific 20mer peptide from the VP1 coat protein of foot-and-mouth-disease virus (FMDV) (forming conjugate SG3299) or to a non-targeting peptide (forming conjugate SG3511). PDCs were tested for specificity and toxicity on αvβ6-negative versus-positive PDAC cells, patient-derived cell lines from tumor xenografts, and on two different in vivo models of PDAC. Immunohistochemical analyses were performed to establish therapeutic mechanism. Results: The αvβ6-targeted PDC SG3299 was significantly more toxic (up to 78-fold) for αvβ6-expressing versus αvβ6-negative PDAC cell lines in vitro, and achieved significantly higher toxicity at equal dose than the non-targeted PDC SG3511 (up to 15-fold better). Moreover, SG3299 eliminated established (100mm(3)) Capan-1 PDAC human xenografts, extending the lifespan of mice significantly (P=0.005). Immunohistochemistry revealed SG3299 induced DNA damage and apoptosis (increased γH2AX and cleaved caspase 3, respectively) associated with significant reductions in proliferation (Ki67), β6 expression and PDAC tumour growth. Conclusions: The FMDV-peptide drug conjugate SG3299 showed αvβ6-selectivity in vitro and in vivo and can specifically eliminate αvβ6-positive cancers, providing a promising new molecular- specific therapy for pancreatic cancer. Ivyspring International Publisher 2020-02-12 /pmc/articles/PMC7053198/ /pubmed/32194845 http://dx.doi.org/10.7150/thno.38702 Text en © The author(s) This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
spellingShingle | Research Paper Moore, Kate M. Desai, Ami Delgado, Bea de Luxán Trabulo, Sara Maria David Reader, Claire Brown, Nicholas F. Murray, Elizabeth R. Brentnall, Adam Howard, Philip Masterson, Luke Zammarchi, Francesca Hartley, John A. van Berkel, Patrick H. Marshall, John F. Integrin αvβ6-specific therapy for pancreatic cancer developed from foot-and-mouth-disease virus |
title | Integrin αvβ6-specific therapy for pancreatic cancer developed from foot-and-mouth-disease virus |
title_full | Integrin αvβ6-specific therapy for pancreatic cancer developed from foot-and-mouth-disease virus |
title_fullStr | Integrin αvβ6-specific therapy for pancreatic cancer developed from foot-and-mouth-disease virus |
title_full_unstemmed | Integrin αvβ6-specific therapy for pancreatic cancer developed from foot-and-mouth-disease virus |
title_short | Integrin αvβ6-specific therapy for pancreatic cancer developed from foot-and-mouth-disease virus |
title_sort | integrin αvβ6-specific therapy for pancreatic cancer developed from foot-and-mouth-disease virus |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053198/ https://www.ncbi.nlm.nih.gov/pubmed/32194845 http://dx.doi.org/10.7150/thno.38702 |
work_keys_str_mv | AT moorekatem integrinavb6specifictherapyforpancreaticcancerdevelopedfromfootandmouthdiseasevirus AT desaiami integrinavb6specifictherapyforpancreaticcancerdevelopedfromfootandmouthdiseasevirus AT delgadobeadeluxan integrinavb6specifictherapyforpancreaticcancerdevelopedfromfootandmouthdiseasevirus AT trabulosaramariadavid integrinavb6specifictherapyforpancreaticcancerdevelopedfromfootandmouthdiseasevirus AT readerclaire integrinavb6specifictherapyforpancreaticcancerdevelopedfromfootandmouthdiseasevirus AT brownnicholasf integrinavb6specifictherapyforpancreaticcancerdevelopedfromfootandmouthdiseasevirus AT murrayelizabethr integrinavb6specifictherapyforpancreaticcancerdevelopedfromfootandmouthdiseasevirus AT brentnalladam integrinavb6specifictherapyforpancreaticcancerdevelopedfromfootandmouthdiseasevirus AT howardphilip integrinavb6specifictherapyforpancreaticcancerdevelopedfromfootandmouthdiseasevirus AT mastersonluke integrinavb6specifictherapyforpancreaticcancerdevelopedfromfootandmouthdiseasevirus AT zammarchifrancesca integrinavb6specifictherapyforpancreaticcancerdevelopedfromfootandmouthdiseasevirus AT hartleyjohna integrinavb6specifictherapyforpancreaticcancerdevelopedfromfootandmouthdiseasevirus AT vanberkelpatrickh integrinavb6specifictherapyforpancreaticcancerdevelopedfromfootandmouthdiseasevirus AT marshalljohnf integrinavb6specifictherapyforpancreaticcancerdevelopedfromfootandmouthdiseasevirus |